Tag: clinical trials
-
New Antimalarial Candidate MK-7602 Shows Promise Against Resistance and Transmission
Breakthrough Candidate in the Fight Against Malaria A new antimalarial drug candidate, MK-7602, is showing early promise in addressing two of the most pressing challenges in malaria control: rising drug resistance and ongoing transmission. Developed as a first-in-class clinical candidate, MK-7602 represents a strategic advance in the global effort to reduce malaria morbidity and move…
-
New Antimalarial Candidate MK-7602 Aims to Beat Resistance and Cut Transmission
Overview of MK-7602 and Why It Matters Researchers have unveiled a first-in-class antimalarial candidate, MK-7602, designed to confront the growing problem of drug resistance and potentially reduce malaria transmission. The program represents a strategic pivot in the field, aiming to deliver a drug with a unique mechanism of action that can stay effective as parasites…
-
New Antibiotics hailed as a Turning Point in Treating Drug-Resistant Gonorrhoea
Hope on the horizon as new antibiotics reach the fight against gonorrhoea Medical researchers are calling a recent breakthrough in antibiotics a potential turning point in the long struggle against drug-resistant gonorrhoea. The sexually transmitted infection has shown a worrying ability to adapt, outpacing many standard treatments and driving global concerns about the rise of…
-
Gene Therapy Brings Hope: Child with Rare Parkinson’s Disease Shows Remarkable Recovery
Hope Emerges from a Groundbreaking Gene Therapy In Singapore, a medical breakthrough has offered new optimism for families affected by a rare form of Parkinson’s disease in children. A successful gene therapy intervention has shown meaningful improvements in motor function, communication, and daily living activities for a young patient, sparking conversations about expanding access to…
-
MS Research Derailed by Stock Market Spoofing: Lawsuit Reveals Market Manipulation Impact
Introduction: A Promising MS Breakthrough Put at Risk A Canadian biotechnology company pursuing a groundbreaking multiple sclerosis (MS) treatment has filed a lawsuit alleging that stock market spoofing and related manipulation behaviors derailed its research funding and strategic decisions. This unfolding case, the first in a series by a W5 investigation, shines a harsh light…
-
Adalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase
Adalyon Names Ulrik Zeuthen as Chief Executive Officer to Lead Next Phase Espoo, Finland, Nov. 25, 2025 — Adalyon, a pioneer in AI-powered speech biomarker technology for clinical drug development, today announced the appointment of Ulrik Zeuthen as Chief Executive Officer. The move signals a strategic push to accelerate the company’s growth trajectory and advance…
-
Townsville man turns adversity into advocacy for pancreatic cancer awareness
Turning a life-changing moment into a cause In Townsville, a life-altering diagnosis propelled one man to champion pancreatic cancer awareness. Malcolm Stephens, 59, learned he had pancreatic cancer after a routine health check following a urinary tract infection. The revelation came quickly and unexpectedly, with doctors recommending further tests that confirmed the diagnosis within days.…
-
UK Trials Examine Puberty Blockers in Young People: Reassessing Evidence and Ethics
Two UK clinical trials investigate puberty blockers in young people Two new clinical trials announced in the United Kingdom aim to examine the effects of puberty blockers for young people experiencing gender incongruence. The investigations come after an expert panel suggested that gender medicine has relied on shaky foundations, prompting calls for more rigorous, transparent…
-
UK Launches Two Trials to Assess Puberty Blockers in Young People with Gender Incongruence
Overview of the Trials Two new clinical trials in the United Kingdom aim to evaluate the effects of puberty blockers on young people experiencing gender incongruence. The studies come after expert commentary calling gender-affirming medicine a field with uncertain scientific foundations. The trials are designed to provide robust data on safety, outcomes, and the potential…
-
UK Launches Two Clinical Trials on Puberty Blockers for Young People with Gender Incongruence
Two UK Clinical Trials Aim to Illuminate Puberty Blockers’ Impact In a move that could shape future treatment guidelines, researchers in the United Kingdom have announced two clinical trials examining the effects of puberty blockers on young people with gender incongruence. The studies come on the back of expert concerns that the medical field of…